Clinical Trial Update: An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils [Phase 3]

View source ↗

Summary

Phase 3 trial update on reslizumab subcutaneous for asthma with eosinophilia and oral corticosteroid dependence; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• reslizumab (reslizumab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Asthma, Elevated Blood Eosinophils | Phase 3 | Status: COMPLETED | Results posted: 2018-09-13